Latest & greatest articles for quinapril

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on quinapril or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on quinapril and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for quinapril

1. [Clinical-instrumental evaluation of the effects of quinapril treatment in mild-to-moderate hypertension]. (Abstract)

[Clinical-instrumental evaluation of the effects of quinapril treatment in mild-to-moderate hypertension]. Eleven patients with uncomplicated mild-to-moderate hypertension (diastolic pressure 95-115 mmHg) were treated for four weeks with daily single quinapril doses of 20-40 mg. Already during the second week a significant reduction in blood pressure was observed without increase of heart rate; 27.3% of patients responded to the lower dose (diastolic blood pressure [90 mmHg], and 54.6

1991 La Clinica terapeutica

2. Quinapril for coronary artery disease. (Abstract)

Quinapril for coronary artery disease. 9153985 1997 06 30 2018 11 30 0970-258X 10 2 1997 Mar-Apr The National medical journal of India Natl Med J India Quinapril for coronary artery disease. 73-4 Seth S S Department of Cardiology, All India Institute of Medical Sciences, New Delhi. Mohan A A eng Clinical Trial Journal Article Randomized Controlled Trial India Natl Med J India 8809315 0970-258X 0 Angiotensin-Converting Enzyme Inhibitors 0 Isoquinolines 0 Prodrugs 0 Tetrahydroisoquinolines (...) RJ84Y44811 Quinapril IM Angiotensin-Converting Enzyme Inhibitors adverse effects therapeutic use Coronary Angiography drug effects Coronary Disease diagnostic imaging drug therapy Coronary Vessels drug effects Double-Blind Method Endothelium, Vascular drug effects Humans Isoquinolines adverse effects therapeutic use Prodrugs adverse effects therapeutic use Quinapril Tetrahydroisoquinolines 1997 3 1 1997 3 1 0 1 1997 3 1 0 0 ppublish 9153985

1997 The National medical journal of India Controlled trial quality: uncertain

3. Effects of quinapril and verapamil versus atenolol on blood pressure during dynamic leg exercise. (Abstract)

Effects of quinapril and verapamil versus atenolol on blood pressure during dynamic leg exercise. 8158427 1994 05 19 2018 11 30 0952-1178 11 5 1993 Dec Journal of hypertension. Supplement : official journal of the International Society of Hypertension J Hypertens Suppl Effects of quinapril and verapamil versus atenolol on blood pressure during dynamic leg exercise. S370-1 Cléroux J J Hypertension Research Unit, CHUL Research Center, Université Laval, Quebec, Canada. Beaulieu M M Lemieux S C SC (...) Lacourcière Y Y eng Clinical Trial Comparative Study Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't England J Hypertens Suppl 8501422 0952-1178 0 Angiotensin-Converting Enzyme Inhibitors 0 Isoquinolines 0 Tetrahydroisoquinolines 50VV3VW0TI Atenolol CJ0O37KU29 Verapamil RJ84Y44811 Quinapril IM Angiotensin-Converting Enzyme Inhibitors administration & dosage therapeutic use Atenolol therapeutic use Blood Pressure drug effects physiology Double-Blind Method Exercise physiology

1994 Journal of hypertension. Supplement : official journal of the International Society of Hypertension Controlled trial quality: uncertain

4. Effect of quinapril versus nitrendipine on endothelial dysfunction in patients with systemic hypertension. (Abstract)

Effect of quinapril versus nitrendipine on endothelial dysfunction in patients with systemic hypertension. 11397368 2001 07 05 2018 11 30 0002-9149 87 12 2001 Jun 15 The American journal of cardiology Am. J. Cardiol. Effect of quinapril versus nitrendipine on endothelial dysfunction in patients with systemic hypertension. 1414-6 Uehata A A Department of Internal Medicine, Self Defense Forces Central Hospital, Tokyo, Japan. uehata@ma.kcom.ne.jp Takase B B Nishioka T T Kitamura K K Akima T T (...) Kurita A A Isojima K K eng Clinical Trial Comparative Study Journal Article Randomized Controlled Trial United States Am J Cardiol 0207277 0002-9149 0 Isoquinolines 0 Tetrahydroisoquinolines 9B627AW319 Nitrendipine RJ84Y44811 Quinapril AIM IM Aged Blood Flow Velocity drug effects Blood Pressure drug effects Brachial Artery diagnostic imaging drug effects Endothelium, Vascular drug effects Female Humans Hypertension diagnostic imaging drug therapy Image Processing, Computer-Assisted Isoquinolines

2001 The American journal of cardiology Controlled trial quality: uncertain

5. Effects of quinapril, losartan and hydralazine on cardiac hypertrophy and β-adrenergic neuroeffector mechanisms in transgenic (mREN2)27 rats Full Text available with Trip Pro

Effects of quinapril, losartan and hydralazine on cardiac hypertrophy and β-adrenergic neuroeffector mechanisms in transgenic (mREN2)27 rats 1. Desensitization of the myocardial beta-adrenergic signal transduction pathway is an important mechanism which is involved in the progression of hypertensive heart disease. The aim of the present study was to evaluate the differential effects of chronic pharmacotherapy with an angiotensin converting enzyme (ACE)-inhibitor, an AT1-receptor antagonist (...) and a direct vasodilator on blood pressure, cardiac hypertrophy and the beta-adrenergic signal transduction. Therefore, transgenic TG(mREN2)27 (TG) rats overexpressing the mouse renin gene were used. This strain is characterized by the development of fulminant hypertension with cardiac hypertrophy. 2. Seven week old heterozygous TG(mREN2)27 rats were treated for 11 weeks with the AT1-receptor antagonist losartan (10 mg kg[-1]), the ACE-inhibitor quinapril (15 mg kg[-1]) and the direct vasodilator

1998 British journal of pharmacology

6. Analysis of the Pharmacokinetic Interaction between Cephalexin and Quinapril by a Nonlinear Mixed-Effect Model Full Text available with Trip Pro

Analysis of the Pharmacokinetic Interaction between Cephalexin and Quinapril by a Nonlinear Mixed-Effect Model Oligopeptidic drugs such as beta-lactams and angiotensin-converting enzyme inhibitors share the same carriers in humans and animals, which results in possible pharmacokinetic interactions. To model such interactions, the effects of quinapril on cephalexin pharmacokinetics were investigated in rats. Blood cephalexin concentrations were measured by liquid chromatography, and the data (...) were analyzed by a noncompartmental method and by fitting a bicompartmental model by a nonlinear mixed-effect modeling approach. Five groups of eight rats were examined. In the first three groups, cephalexin elimination kinetics after intra-arterial administration alone or in combination with quinapril given by the parenteral or the oral route were studied, and the occurrence of a pharmacokinetic interaction was not revealed. The absence of an effect of quinapril on cephalexin elimination after

1998 Antimicrobial Agents and Chemotherapy

7. Quinapril

Quinapril Top results for quinapril - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for quinapril The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

8. Quinapril decreases antifibrinolytic and prooxidative potential of propofol in arterial thrombosis in hypertensive rats Full Text available with Trip Pro

Quinapril decreases antifibrinolytic and prooxidative potential of propofol in arterial thrombosis in hypertensive rats Angiotensin converting enzyme inhibitors and propofol both exert hypotensive action and may affect hemostasis. We investigated the influence of quinapril and propofol on hemodynamics and hemostasis in renal-hypertensive rats with induced arterial thrombosis. Two-kidney, one clip hypertensive rats were treated with quinapril (3.0 mg/kg for 10 days), and then received propofol (...) infusion (15 mg/kg/h) during ongoing arterial thrombosis. The hemodynamic and hemostatic parameters were assayed. Quinapril exerted a hypotensive effect increasing after propofol infusion. Quinapril showed an antithrombotic effect with the platelet adhesion reduction, fibrinolysis enhancement and oxidative stress reduction. Propofol did not influence thrombosis; however, it inhibited fibrinolysis and showed prooxidative action. The effect of propofol on fibrinolysis and oxidative stress

2016 Journal of the Renin-Angiotensin-Aldosterone System: JRAAS

9. Bioequivalence Study of Quinapril Hydrochloride 20 mg and Hydrochlorothiazide 25 mg Tablets Under Fed Conditions

Bioequivalence Study of Quinapril Hydrochloride 20 mg and Hydrochlorothiazide 25 mg Tablets Under Fed Conditions Bioequivalence Study of Quinapril Hydrochloride 20 mg and Hydrochlorothiazide 25 mg Tablets Under Fed Conditions - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved (...) studies (100). Please remove one or more studies before adding more. Bioequivalence Study of Quinapril Hydrochloride 20 mg and Hydrochlorothiazide 25 mg Tablets Under Fed Conditions The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00872235 Recruitment Status : Completed First Posted : March 31, 2009

2009 Clinical Trials

10. Bioequivalence Study of Quinapril Hydrochloride 20 mg and Hydrochlorothiazide 25 mg Tablets Under Fasting Conditions

Bioequivalence Study of Quinapril Hydrochloride 20 mg and Hydrochlorothiazide 25 mg Tablets Under Fasting Conditions Bioequivalence Study of Quinapril Hydrochloride 20 mg and Hydrochlorothiazide 25 mg Tablets Under Fasting Conditions - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number (...) of saved studies (100). Please remove one or more studies before adding more. Bioequivalence Study of Quinapril Hydrochloride 20 mg and Hydrochlorothiazide 25 mg Tablets Under Fasting Conditions The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00872781 Recruitment Status : Completed First Posted : March

2009 Clinical Trials

11. Effects of Quinapril 40 mg With Alpha Lipoic Acid or Placebo on Diabetes and Hypertension

Effects of Quinapril 40 mg With Alpha Lipoic Acid or Placebo on Diabetes and Hypertension Effects of Quinapril 40 mg With Alpha Lipoic Acid or Placebo on Diabetes and Hypertension - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more (...) studies before adding more. Effects of Quinapril 40 mg With Alpha Lipoic Acid or Placebo on Diabetes and Hypertension (QUALITY) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00795262 Recruitment Status : Completed First Posted : November 21, 2008 Last Update Posted : May 5, 2011 Sponsor: InVasc

2008 Clinical Trials

12. Quinapril treatment abolishes diabetes-associated atherosclerosis in RAGE/apolipoprotein E double knockout mice. (Abstract)

Quinapril treatment abolishes diabetes-associated atherosclerosis in RAGE/apolipoprotein E double knockout mice. Both the renin-angiotensin system (RAS) and the receptor for advanced glycation end products (RAGE) potentiate diabetes-associated atherosclerosis (DAA). We assessed the effectiveness of concomitant RAS and RAGE inhibition on DAA.Diabetic (5 × 55 mg/kg streptozotocin daily) and non-diabetic male RAGE/apolipoprotein E double knockout (RAGE/apoE DKO) mice were treated with quinapril (...) (30 mg/kg/day) for 20 weeks. At the end of the study aortic plaques were assessed.Diabetic RAGE/apoE DKO showed significantly less plaque area than diabetic apoE KO mice. Plaque deposition was almost abolished in quinapril treated diabetic RAGE/apoE DKOs, with significant attenuation of vascular collagen deposition, nitrotyrosine staining, and reduced macrophage infiltration. Expression of the advanced glycation end product receptor 3 (galectin 3) was also significantly reduced.Concomitant

2014 Atherosclerosis

13. A Study to Evaluate the Efficacy and Safety of Quinapril or Quinapril Plus Hydrochlorothiazide in Patients With Mild to Moderate Hypertension

A Study to Evaluate the Efficacy and Safety of Quinapril or Quinapril Plus Hydrochlorothiazide in Patients With Mild to Moderate Hypertension A Study to Evaluate the Efficacy and Safety of Quinapril or Quinapril Plus Hydrochlorothiazide in Patients With Mild to Moderate Hypertension - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save (...) this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Study to Evaluate the Efficacy and Safety of Quinapril or Quinapril Plus Hydrochlorothiazide in Patients With Mild to Moderate Hypertension The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details

2008 Clinical Trials

14. Food Study of Quinapril Hydrochloride Tablets 40 mg and Accupril® Tablets 40 mg

Food Study of Quinapril Hydrochloride Tablets 40 mg and Accupril® Tablets 40 mg Food Study of Quinapril Hydrochloride Tablets 40 mg and Accupril® Tablets 40 mg - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding (...) more. Food Study of Quinapril Hydrochloride Tablets 40 mg and Accupril® Tablets 40 mg The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00649649 Recruitment Status : Completed First Posted : April 1, 2008 Last Update Posted : April 1, 2008 Sponsor: Mylan Pharmaceuticals Information provided by: Mylan

2008 Clinical Trials

15. Food Study of Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Accureticâ„¢ Tablets 20 mg/25 mg

Food Study of Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Accureticâ„¢ Tablets 20 mg/25 mg Food Study of Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Accuretic™ Tablets 20 mg/25 mg - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100 (...) ). Please remove one or more studies before adding more. Food Study of Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Accuretic™ Tablets 20 mg/25 mg The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00648011 Recruitment Status : Completed First Posted : April 1, 2008 Last Update Posted

2008 Clinical Trials

16. Fasting Study of Quinapril Hydrochloride Tablets 40 mg and Accupril® Tablets 40 mg

Fasting Study of Quinapril Hydrochloride Tablets 40 mg and Accupril® Tablets 40 mg Fasting Study of Quinapril Hydrochloride Tablets 40 mg and Accupril® Tablets 40 mg - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before (...) adding more. Fasting Study of Quinapril Hydrochloride Tablets 40 mg and Accupril® Tablets 40 mg The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00649103 Recruitment Status : Completed First Posted : April 1, 2008 Last Update Posted : April 1, 2008 Sponsor: Mylan Pharmaceuticals Information provided

2008 Clinical Trials

17. Fasting Study of Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Accureticâ„¢ Tablets 20 mg/25 mg

Fasting Study of Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Accureticâ„¢ Tablets 20 mg/25 mg Fasting Study of Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Accuretic™ Tablets 20 mg/25 mg - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (...) (100). Please remove one or more studies before adding more. Fasting Study of Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Accuretic™ Tablets 20 mg/25 mg The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00649441 Recruitment Status : Completed First Posted : April 1, 2008 Last Update

2008 Clinical Trials

18. High-Dose Quinapril Versus Low-Dose Quinapril Plus Amlodipine in the Treatment of High-Risk Hypertensive Patients

High-Dose Quinapril Versus Low-Dose Quinapril Plus Amlodipine in the Treatment of High-Risk Hypertensive Patients High-Dose Quinapril Versus Low-Dose Quinapril Plus Amlodipine in the Treatment of High-Risk Hypertensive Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved (...) studies (100). Please remove one or more studies before adding more. High-Dose Quinapril Versus Low-Dose Quinapril Plus Amlodipine in the Treatment of High-Risk Hypertensive Patients The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00313547 Recruitment Status : Terminated (Very difficult to recruit

2006 Clinical Trials

19. A Non Interventional Study To Asses The Safety, Effectiveness And Tolerability Of Quinapril (Acupil®) In An Indian Population

A Non Interventional Study To Asses The Safety, Effectiveness And Tolerability Of Quinapril (Acupil®) In An Indian Population A Non Interventional Study To Asses The Safety, Effectiveness And Tolerability Of Quinapril (Acupil®) In An Indian Population - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached (...) the maximum number of saved studies (100). Please remove one or more studies before adding more. A Non Interventional Study To Asses The Safety, Effectiveness And Tolerability Of Quinapril (Acupil®) In An Indian Population (ASSET) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00930722 Recruitment Status

2009 Clinical Trials

20. Lack of efficacy of quinapril on vascular damage in limited cutaneous systemic sclerosis. (Abstract)

Lack of efficacy of quinapril on vascular damage in limited cutaneous systemic sclerosis. Gliddon et al. conducted a randomized, double-blind, multicenter, placebo-controlled study to evaluate the efficacy of the angiotensin-converting enzyme inhibitor quinapril for the management of vascular damage in systemic sclerosis (SSc). The trial comprised 213 patients with limited cutaneous SSc or Raynaud's phenomenon (mean age 54 years, 182 females) who were randomly assigned to receive 80 mg/day (...) , or the maximum tolerated dose, of quinapril (n = 105) or placebo (n = 108) for 2-3 years. Patients were assessed every 3 months. The number of new ischemic digital ulcers was recorded as the primary end point, while the frequency of Raynaud's phenomenon episodes, skin score, health status, pulmonary artery pressure and treatments for ischemia were also monitored as secondary end points. There were no detectable differences between patients treated with quinapril and those receiving placebo; however, although

2008 Nature clinical practice. Rheumatology Controlled trial quality: predicted high